Skip to main content

Table 2 Comparison of different interventional therapy (n = 10, each group)

From: Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia

Variables

Sham

Control

Atorvastatin

Rosiglitazone

Combined

TG (mmol/L)

     

TC (mmol/L)

3.31 ± 0.40*

4.99 ± 0.57

4.35 ± 0.65

4.92 ± 0.66

4.33 ± 0.64

LDL-C (mmol/L)

1.92 ± 0.38*

3.04 ± 0.44

2.77 ± 0.49

3.01 ± 0.71

2.88 ± 0.56

HDL-C (mmol/L)

0.89 ± 0.17

0.89 ± 0.12

0.89 ± 0.08

0.88 ± 0.25

0.86 ± 0.27

FBG (mmol/L)

4.44 ± 0.27

4.52 ± 0.43

4.62 ± 0.30

4.57 ± 0.50

4.49 ± 0.36

NO (umol/L)

10.61 ± 1.23*

6.04 ± 1.02#

7.53 ± 1.11

7.86 ± 1.07

8.41 ± 1.30&

MDA (nmol/mL)

0.95 ± 0.04*

3.97 ± 0.55#

3.26 ± 0.23

3.38 ± 0.27

2.52 ± 0.04&

CRP (mg/L)

1.97 ± 0.17*

4.64 ± 0.75#

3.96 ± 0.37

4.07 ± 0.28

3.26 ± 0.67&

ADMA (nmol/L)

47.38 ± 5.02*

67.15 ± 7.34#

58.09 ± 6.92

59.48 ± 6.11

53.34 ± 5.58&

15-d-PGJ 2 (pg/mL)

18.45 ± 1.23

21.66 ± 3.45#

30.40 ± 5.08

32.23 ± 5.53

37.26 ± 6.16&

  1. Denote: *p <0.05 versus other groups; #p <0.05 versus atorvastatin, rosiglitazone and combined groups; &p <0.05 versus atorvastatin and rosiglitazone groups.